Mark Breidenbach
Stock Analyst at Oppenheimer
(1.69)
# 3,290
Out of 5,182 analysts
48
Total ratings
30.91%
Success rate
1.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $2.15 | +225.58% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $16.81 | +78.47% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $10.51 | +803.90% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $5.37 | +365.55% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $300 | $30.42 | +886.19% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $7.61 | +3,053.75% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.86 | +5,488.15% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.71 | +158.30% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.87 | +1,611.23% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $3.40 | +341.18% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.75 | +1,292,317.82% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $2.15
Upside: +225.58%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $16.81
Upside: +78.47%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $10.51
Upside: +803.90%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $5.37
Upside: +365.55%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $300
Current: $30.42
Upside: +886.19%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $7.61
Upside: +3,053.75%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.86
Upside: +5,488.15%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.71
Upside: +158.30%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.87
Upside: +1,611.23%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $3.40
Upside: +341.18%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.75
Upside: +1,292,317.82%